CRISPR Therapeutics AG (CRSP) Assets (2015 - 2026)

CRISPR Therapeutics AG has disclosed Assets across 12 years of filings, most recently posting $2.7 billion for Q1 2026.

• Assets for Q1 2026 came in at $2.7 billion, up 25.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.7 billion (up 25.84% YoY), and the FY2025 annual result was $2.3 billion, up 1.04% from the prior year.
• Assets came in at $2.7 billion for Q1 2026 at CRISPR Therapeutics AG, up from $2.3 billion in the prior quarter.
• In the past five years, Assets ranged from a high of $2.7 billion in Q1 2026 to a low of $2.0 billion in Q2 2025.
• The 5-year median for Assets is $2.2 billion (2025), against an average of $2.3 billion.
• Peak annual rise in Assets reached 33.11% in 2022, while the deepest fall reached 18.49% in 2022.
• CRISPR Therapeutics AG's Assets stood at $2.2 billion in 2022, then dropped by 0.6% to $2.2 billion in 2023, then advanced by 0.56% to $2.2 billion in 2024, then grew by 1.04% to $2.3 billion in 2025, then advanced by 20.33% to $2.7 billion in 2026.
• The last three Assets figures came in at $2.7 billion (Q1 2026), $2.3 billion (Q4 2025), and $2.2 billion (Q3 2025), per Business Quant data.